FDA approves Janssen’s Rybrevant
First targeted treatment authorised in the US for NSCLC patients with EGFR exon 20 insertion mutations
Read More
Tag: EGFR
Janssen eyes US approval for EGFR-targeting NSCLC therapy
Bispecific antibody targets EGFR and MET mutated tumours
Read More
US widens use of AZ’ Tagrisso in lung cancer
AstraZeneca’s Tagrisso has been approved in the US as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) mutations.
Read More
US expands scope of BI’s lung cancer drug Gilotrif
US regulators have approved a supplemental New Drug Application for Boehringer Ingelheim’s lung cancer drug Gilotrif for first-line treatment of patients with metastatic non-small cell lung cancer whose tumours have non-resistant epidermal growth factor receptor.
Read More
US priority review for AZ’ Tagrisso
US regulators are undertaking a speedy review of AstraZeneca’s application to market Tagrisso as first-line treatment for lung cancer.
Read More
FDA hands over full approval to AZ’ Tagrisso
US regulators have issued a full approval of AstraZeneca’s lung cancer drug Tagrisso on the back of a strong progression-free survival (PFS) benefit observed in a late-stage trial.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
